Modified AAV Capsids With Ligand Targeting for Specific Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current AAV gene therapies suffer from limited transduction efficiency and specificity, leading to off-target transduction and toxicity, particularly in liver, and ineffective delivery to specific cell types, necessitating high viral titers and extensive preclinical and clinical characterization.
Innovation Solution
Chemical modification of AAV capsids to accept ligand attachment through crosslinked moieties formed by crosslinker reactive pairs, such as CuAAC or SPAAC reactions, allowing for targeted delivery by removing natural binding sites and incorporating cell-type specific ligands like cytokines or peptides.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If AAV capsids are modified to enhance transduction efficiency, then transduction efficiency is improved, but off-target transduction and toxicity increase
Solution Approach 1:
The patent applies local quality by modifying specific regions of the AAV capsid protein (VP1, VP2, or VP3) at particular amino acid positions to alter binding properties. By making localized changes to the capsid surface rather than global modifications, the invention achieves enhanced transduction efficiency for target tissues while reducing off-target effects, as the modified capsid maintains specificity for intended cell types.
Solution Approach 2:
The patent employs parameter changes by mutating specific amino acid residues in the capsid protein sequence to alter the physical-chemical properties of the capsid surface. These parameter changes in the capsid structure modify its binding affinity and specificity, enabling improved transduction efficiency while reducing unwanted interactions with non-target tissues.
2Productivity
If high viral titers are used to achieve effective transduction, then transduction efficiency is improved, but immunogenicity and toxicity increase
Solution Approach 1:
The patent applies parameter changes by modifying the capsid protein's amino acid sequence to alter its biological properties, specifically its binding affinity and tissue tropism. These parameter changes enable the virus to achieve effective transduction at lower titers by improving its ability to recognize and enter target cells, thereby reducing the need for high viral doses that would otherwise cause immunogenicity and toxicity.
Solution Approach 2:
The patent substitutes the mechanical approach of increasing viral dose (quantity) with a biochemical approach of modifying capsid properties (quality). Instead of relying on high viral titers to overcome poor transduction efficiency, the invention uses rational capsid design to enhance cellular uptake and transduction efficiency, allowing effective gene delivery at lower, safer viral concentrations.
3Manufacturing precision
If natural binding sites are removed from AAV capsids, then specificity is improved, but production efficiency decreases
Solution Approach 1:
The patent applies local quality by making targeted mutations at specific amino acid positions in the capsid protein rather than extensive modifications throughout the entire capsid structure. This localized approach to removing or modifying natural binding sites achieves improved specificity while minimizing disruption to the overall capsid assembly process and production efficiency.
Solution Approach 2:
The patent employs parameter changes by introducing point mutations or small changes in the amino acid sequence at specific positions to alter binding properties. These parameter changes are designed to achieve the desired specificity improvement while maintaining compatibility with existing production methods and efficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enhances transduction efficiency and specificity to targeted cells, reducing off-target effects and immunogenicity, while maintaining production efficiency and enabling lower viral titers for effective gene therapy.
Implementation Method 1
Chemical modification of AAV capsids to accept ligand attachment through crosslinked moieties formed by crosslinker reactive pairs, such as CuAAC or SPAAC reactions
Implementation Method 2
Chemical modification of AAV capsids to accept ligand attachment through crosslinked moieties formed by crosslinker reactive pairs, such as CuAAC or SPAAC reactions
Data Source
AI summary
This invention relates to novel surface modified viral capsids and recombinant virions comprising the same. Furthermore, this invention concerns intermediates for the preparation of surface modified viral capsids. The surface modified viral capsids are designed to selectively and/or more efficiently deliver gene therapy. The surface modified viral capsids, when incorporated into a recombinant virion, can be used to treat an illness that is characterized by genetic abnormality.